Genetic mutations link could lead to new therapies for AML

Leukemia & Lymphoma Society renamed Blood Cancer United

The Leukemia & Lymphoma Society is becoming Blood Cancer United on August 28 in advance of Blood Cancer Awareness Month in September.

August 01, 2025

Vol.51 No.30

Clinical Roundup

IGRT shows no reduction in serious infections for patients with CLL

Regular treatment with immunoglobulin replacement therapy in patients with chronic lymphocytic leukemia was not associated with a reduced risk of serious infections requiring hospitalization, according to a study published in Blood Advances.

August 01, 2025

Vol.51 No.30

Clinical Roundup

Ohio State launches pancreatic cancer trial via telehealth

The Ohio State University Comprehensive Cancer has launched a first-of-its-kind clinical trial.

July 18, 2025

Vol.51 No.28

Drugs & Targets

China’s NMPA approves lisaftoclax for CLL or SLL

The National Medical Products Administration in China approved lisaftoclax (APG-2575), a Bcl-2 selective inhibitor, for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors.

July 11, 2025

Vol.51 No.27

Podcast

In The Headlines: Kimryn Rathmell, ASCO, and “an important time in cancer research”

“Patients are counting on us, and this remains the best time to be involved in cancer research,” W. Kimryn Rathmell said to The Cancer Letter.

June 04, 2025

Vol.51 No.21

Conversation with The Cancer Letter

We catch up with Kimryn Rathmell on her first day as CEO at OSUCCC – James

At the end of her first day on the job as CEO of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, W. Kimryn Rathmell reflected on her decision to take the CEO job at the third largest cancer hospital in the United States.

May 30, 2025

Vol.51 No.21

By Paul Goldberg